Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE CLINICAL RELEVANCE OF STATIC DISEASE (NO CHANGE) CATEGORY FOR 6 MONTHS ON ENDOCRINE THERAPY IN PATIENTS WITH BREAST-CANCER
Autore:
ROBERTSON JFR; WILLSHER PC; CHEUNG KL; BLAMEY RW;
Indirizzi:
CITY HOSP NOTTINGHAM NG5 1PB ENGLAND
Titolo Testata:
European journal of cancer
fascicolo: 11, volume: 33, anno: 1997,
pagine: 1774 - 1779
SICI:
0959-8049(1997)33:11<1774:TCROSD>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
AMINOGLUTETHIMIDE; CARCINOMA; TAMOXIFEN; TRIAL;
Keywords:
BREAST CANCER; ENDOCRINE THERAPY; STATIC DISEASE;
Tipo documento:
Article
Natura:
Periodico
Citazioni:
13
Recensione:
Indirizzi per estratti:
Citazione:
J.F.R. Robertson et al., "THE CLINICAL RELEVANCE OF STATIC DISEASE (NO CHANGE) CATEGORY FOR 6 MONTHS ON ENDOCRINE THERAPY IN PATIENTS WITH BREAST-CANCER", European journal of cancer, 33(11), 1997, pp. 1774-1779

Abstract

This study reports on the clinical relevance of the static disease (SD) category in 255 breast cancer patients on endocrine therapy. All patients had received first-and second-line endocrine therapy and were assessed for response by the International Union Against Cancer (UICC) criteria. We did not include patients who received first-line endocrine therapy but did not or have not yet proceeded to second-line hormonetherapy, e.g. died from rapidly progressive disease, started chemotherapy for rapidly progressive disease, remained in long-term remission on first-line endocrine therapy. We analysed survival from initiation of first-line endocrine therapy by the remission criteria, i.e. complete response (CR), partial response (PR), static disease (SD) or progressive disease (PD), achieved on that therapy. Patients were divided into those with metastatic breast cancer (MBC) and non-metastatic disease. There was no significant difference in survival from starting first-line endocrine therapy between patients who obtained CR, PR or SD: all three groups of patients survived significantly longer than patientswho showed PD within 6 months (all P < 0.0001 except CR versus PD [MBC] which was P < 0.002). Equally, for second-line endocrine therapy there was no difference in survival between patients who obtained CR, PRor SD: all three groups (CR, PR and SD) survived significantly longerthan PD (all P < 0.0003 except for CR versus PD which was P < 0.003 for non-metastatic and P < 0.059 for MBC). Durable SD appears to be a clinically useful criteria of therapeutic remission. (C) 1997 Elsevier Science Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 20:15:08